Key result
Circulating oxidized LDL is linked to subclinical atherosclerosis and increased clinical ASCVD events.
Review highlights the role of circulating oxidized low-density lipoprotein in atherosclerotic cardiovascular disease, indicating its value as a pathogenic biomarker.
Atherosclerosis is a chronic, progressive disease which eventually leads to coronary heart disease (CHD), ischemic stroke and other atherosclerotic cardiovascular disease (ASCVD). Numerous studies have demonstrated an atherogenic role of oxidized low-density lipoprotein (ox-LDL) in the progression of ASCVD. This article briefly reviews the atherogenic mechanism of ox-LDL, the methods of measuring ox-LDL in the circulation, effect of medical therapy and life-style modification on ox-LDL level, and the association between circulating ox-LDL and atherosclerosis, including clinical ASCVD events and subclinical atherosclerosis, in observational studies.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2017) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). Circulating oxidized low-density lipoprotein (ox-LDL) was evaluated on Clinical ASCVD events and subclinical atherosclerosis. Circulating oxidized low-density lipoprotein plays an atherogenic role and is associated with subclinical atherosclerosis and clinical ASCVD events in observational studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: